GlobeNewsWire
17 Jul 2026, 11:32 UTC · 9w ago
Verdict
Headline takes no side. We score CMND +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA has released final guidance on psychedelic clinical investigations and planned a public hearing on their therapeutic use.
More positive than 92% of claims this week
Multiple U.S. government agencies, including the HHS, VA, and FDA, have established new Memoranda of Understanding and collaborative initiatives for neuropsychiatric treatments.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
Clearmind Medicine's lead candidate, CMND-100, is currently in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder at Yale and Johns Hopkins.
So whatActive clinical trials at prestigious institutions provide a concrete catalyst for future valuation increases based on data readouts.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company views new FDA guidance and federal momentum in psychedelic therapies as significant positive regulatory developments for its pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
−58.3%
Price is moving against the score
$0.8291 vs $1.99 close before publication (Jul 16) · not market-adjusted
CMND chart →
